Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 107

1.

Staging for Breast Cancer Patients Receiving Neoadjuvant Chemotherapy: Utility of Incorporating Biologic Factors.

Yi M, Lin H, Bedrosian I, Shen Y, Hunt KK, Chavez-MacGregor M, King TA, Mittendorf EA.

Ann Surg Oncol. 2019 Oct 30. doi: 10.1245/s10434-019-07983-8. [Epub ahead of print]

PMID:
31667721
2.

Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation.

Xing Y, Lin NU, Maurer MA, Chen H, Mahvash A, Sahin A, Akcakanat A, Li Y, Abramson V, Litton J, Chavez-MacGregor M, Valero V, Piha-Paul SA, Hong D, Do KA, Tarco E, Riall D, Eterovic AK, Wulf GM, Cantley LC, Mills GB, Doyle LA, Winer E, Hortobagyi GN, Gonzalez-Angulo AM, Meric-Bernstam F.

Breast Cancer Res. 2019 Jul 5;21(1):78. doi: 10.1186/s13058-019-1154-8.

3.

Neoadjuvant Chemotherapy does not Increase Complications in Oncoplastic Breast-Conserving Surgery.

Adamson K, Chavez-MacGregor M, Caudle A, Smith B, Baumann D, Liu J, Schaverien M.

Ann Surg Oncol. 2019 Sep;26(9):2730-2737. doi: 10.1245/s10434-019-07408-6. Epub 2019 Apr 29.

PMID:
31037439
4.

High-Cost Hospitalizations Among Elderly Patients With Cancer.

Avila J, Jupiter D, Chavez-MacGregor M, de Oliveira C, Kaul S.

J Oncol Pract. 2019 May;15(5):e447-e457. doi: 10.1200/JOP.18.00706. Epub 2019 Apr 4.

PMID:
30946640
5.

Cost-Effectiveness Analysis of Hepatitis B Virus Screening and Management in Patients With Hematologic or Solid Malignancies Anticipating Immunosuppressive Cancer Therapy.

Hwang JP, Huang D, Vierling JM, Suarez-Almazor ME, Shih YT, Chavez-MacGregor M, Duan Z, Giordano SH, Hershman DL, Fisch MJ, Cantor SB.

JCO Clin Cancer Inform. 2019 Mar;3:1-12. doi: 10.1200/CCI.18.00097.

6.

How we use hospice: Hospice enrollment patterns and costs in elderly ovarian cancer patients.

Taylor JS, Zhang N, Rajan SS, Chavez-MacGregor M, Zhao H, Niu J, Meyer LA, Ramondetta LM, Bodurka DC, Lairson DR, Giordano SH.

Gynecol Oncol. 2019 Mar;152(3):452-458. doi: 10.1016/j.ygyno.2018.10.041.

PMID:
30876488
7.

Clinical Outcomes Associated with Drug-Drug Interactions of Oral Chemotherapeutic Agents: A Comprehensive Evidence-Based Literature Review.

Sharma M, Vadhariya A, Chikermane S, Gopinathan S, Chavez-MacGregor M, Giordano SH, Johnson ML, Holmes HM.

Drugs Aging. 2019 Apr;36(4):341-354. doi: 10.1007/s40266-019-00640-5.

PMID:
30714077
8.

Clinical Cancer Advances 2019: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.

Pal SK, Miller MJ, Agarwal N, Chang SM, Chavez-MacGregor M, Cohen E, Cole S, Dale W, Magid Diefenbach CS, Disis ML, Dreicer R, Graham DL, Henry NL, Jones J, Keedy V, Klepin HD, Markham MJ, Mittendorf EA, Rodriguez-Galindo C, Sabel MS, Schilsky RL, Sznol M, Tap WD, Westin SN, Johnson BE.

J Clin Oncol. 2019 Apr 1;37(10):834-849. doi: 10.1200/JCO.18.02037. Epub 2019 Jan 31. No abstract available.

PMID:
30702028
9.

Geographic Distribution and Survival Outcomes for Rural Patients With Cancer Treated in Clinical Trials.

Unger JM, Moseley A, Symington B, Chavez-MacGregor M, Ramsey SD, Hershman DL.

JAMA Netw Open. 2018 Aug 3;1(4):e181235. doi: 10.1001/jamanetworkopen.2018.1235.

10.

Hospitalization by cytotoxic chemotherapy regimen among older women with stage IV breast cancer.

Kehl KL, Niu J, Chavez-MacGregor M, Giordano SH.

Cancer. 2018 Dec 15;124(24):4685-4691. doi: 10.1002/cncr.31760. Epub 2018 Sep 28.

PMID:
30264853
11.

Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer.

Basho RK, Yam C, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Hong D, Kurzrock R, Hortobagyi GN, Janku F, Moulder SL.

Oncologist. 2018 Nov;23(11):1300-1309. doi: 10.1634/theoncologist.2017-0498. Epub 2018 Aug 23.

12.

Long-Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2-Targeted Therapy.

Wong Y, Raghavendra AS, Hatzis C, Irizarry JP, Vega T, Horowitz N, Barcenas CH, Chavez-MacGregor M, Valero V, Tripathy D, Pusztai L, Murthy RK.

Oncologist. 2019 Mar;24(3):313-318. doi: 10.1634/theoncologist.2018-0213. Epub 2018 Aug 23.

PMID:
30139836
13.

ASCO Resource-Stratified Guidelines: Methods and Opportunities.

Al-Sukhun S, Temin S, Chavez-MacGregor M, Denduluri N, Oliver TK, Pyle D, Shah MA, Gralow J.

J Glob Oncol. 2018 Jul;4:1-8. doi: 10.1200/JGO.18.00113.

14.

Cardiotoxicity and Cardiac Monitoring Among Chemotherapy-Treated Breast Cancer Patients.

Henry ML, Niu J, Zhang N, Giordano SH, Chavez-MacGregor M.

JACC Cardiovasc Imaging. 2018 Aug;11(8):1084-1093. doi: 10.1016/j.jcmg.2018.06.005.

15.

Diagnosis of brain metastases in breast cancer patients resulting from neurological symptoms.

Cacho-Díaz B, Spínola-Maroño H, Arrieta VA, Granados-García M, Wegman-Ostrosky T, Mendoza-Olivas LG, Chávez-MacGregor M.

Clin Neurol Neurosurg. 2018 Oct;173:61-64. doi: 10.1016/j.clineuro.2018.08.002. Epub 2018 Aug 2.

PMID:
30086430
16.

American Society of Breast Surgeons' Practice Patterns After Publication of the SSO-ASTRO-ASCO DCIS Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation.

DeSnyder SM, Hunt KK, Dong W, Smith BD, Moran MS, Chavez-MacGregor M, Shen Y, Kuerer HM, Lucci A.

Ann Surg Oncol. 2018 Oct;25(10):2965-2974. doi: 10.1245/s10434-018-6580-9. Epub 2018 Jul 9.

PMID:
29987598
17.

Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update.

Denduluri N, Chavez-MacGregor M, Telli ML, Eisen A, Graff SL, Hassett MJ, Holloway JN, Hurria A, King TA, Lyman GH, Partridge AH, Somerfield MR, Trudeau ME, Wolff AC, Giordano SH.

J Clin Oncol. 2018 Aug 10;36(23):2433-2443. doi: 10.1200/JCO.2018.78.8604. Epub 2018 May 22.

PMID:
29787356
18.

Delays in Adjuvant Chemotherapy Among Breast Cancer Patients: An Unintended Consequence of Breast Surgery?

de Melo Gagliato D, Chavez-MacGregor M.

Ann Surg Oncol. 2018 Jul;25(7):1786-1787. doi: 10.1245/s10434-018-6415-8. Epub 2018 Mar 29. No abstract available.

PMID:
29600346
19.

Survival by Hispanic ethnicity among patients with cancer participating in SWOG clinical trials.

Chavez-MacGregor M, Unger JM, Moseley A, Ramsey SD, Hershman DL.

Cancer. 2018 Apr 15;124(8):1760-1769. doi: 10.1002/cncr.31241. Epub 2018 Jan 25.

20.

Acute myeloid leukemia and myelodysplastic syndrome after adjuvant chemotherapy: A population-based study among older breast cancer patients.

Rosenstock AS, Niu J, Giordano SH, Zhao H, Wolff AC, Chavez-MacGregor M.

Cancer. 2018 Mar 1;124(5):899-906. doi: 10.1002/cncr.31144. Epub 2017 Dec 13.

21.

Validation Study of the American Joint Committee on Cancer Eighth Edition Prognostic Stage Compared With the Anatomic Stage in Breast Cancer.

Weiss A, Chavez-MacGregor M, Lichtensztajn DY, Yi M, Tadros A, Hortobagyi GN, Giordano SH, Hunt KK, Mittendorf EA.

JAMA Oncol. 2018 Feb 1;4(2):203-209. doi: 10.1001/jamaoncol.2017.4298.

22.

Extended adjuvant therapy in patients with HER2-positive breast cancer: some answers, even more questions.

Chavez-MacGregor M, Mittendorf EA.

Lancet Oncol. 2017 Dec;18(12):1568-1569. doi: 10.1016/S1470-2045(17)30844-6. Epub 2017 Nov 13. No abstract available.

PMID:
29146400
23.

Adherence to treatment guidelines and survival for older patients with stage II or III colon cancer in Texas from 2001 through 2011.

Zhao H, Zhang N, Ho V, Ding M, He W, Niu J, Yang M, Du XL, Zorzi D, Chavez-MacGregor M, Giordano SH.

Cancer. 2018 Feb 15;124(4):679-687. doi: 10.1002/cncr.31094. Epub 2017 Nov 15.

24.

The next era of treatment for hormone receptor-positive, HER2-negative advanced breast cancer: Triplet combination-based endocrine therapies.

Cortés J, Im SA, Holgado E, Perez-Garcia JM, Schmid P, Chavez-MacGregor M.

Cancer Treat Rev. 2017 Dec;61:53-60. doi: 10.1016/j.ctrv.2017.09.011. Epub 2017 Oct 12. Review.

25.

DCIS Margins and Breast Conservation: MD Anderson Cancer Center Multidisciplinary Practice Guidelines and Outcomes.

Kuerer HM, Smith BD, Chavez-MacGregor M, Albarracin C, Barcenas CH, Santiago L, Edgerton ME, Rauch GM, Giordano SH, Sahin A, Krishnamurthy S, Woodward W, Tripathy D, Yang WT, Hunt KK.

J Cancer. 2017 Aug 22;8(14):2653-2662. doi: 10.7150/jca.20871. eCollection 2017. Review.

26.

All HER2-Positive Tumors are not Created Equal.

Mittendorf EA, Chavez-MacGregor M.

Ann Surg Oncol. 2017 Nov;24(12):3471-3474. doi: 10.1245/s10434-017-6053-6. Epub 2017 Aug 16. No abstract available.

PMID:
28815451
27.

Ductal Carcinoma In Situ and Margins <2 mm: Contemporary Outcomes With Breast Conservation.

Tadros AB, Smith BD, Shen Y, Lin H, Krishnamurthy S, Lucci A, Barcenas CH, Hwang RF, Rauch G, Santiago L, Strom EA, DeSnyder SM, Yang WT, Black DM, Albarracin CT, Chavez-MacGregor M, Hunt KK, Kuerer HM.

Ann Surg. 2019 Jan;269(1):150-157. doi: 10.1097/SLA.0000000000002439.

PMID:
28742682
28.

Bioscore: A Staging System for Breast Cancer Patients that Reflects the Prognostic Significance of Underlying Tumor Biology.

Mittendorf EA, Chavez-MacGregor M, Vila J, Yi M, Lichtensztajn DY, Clarke CA, Giordano SH, Hunt KK.

Ann Surg Oncol. 2017 Nov;24(12):3502-3509. doi: 10.1245/s10434-017-6009-x. Epub 2017 Jul 19.

29.

Incorporating Tumor Characteristics to the American Joint Committee on Cancer Breast Cancer Staging System.

Chavez-MacGregor M, Mittendorf EA, Clarke CA, Lichtensztajn DY, Hunt KK, Giordano SH.

Oncologist. 2017 Nov;22(11):1292-1300. doi: 10.1634/theoncologist.2017-0116. Epub 2017 Jun 7.

30.

Association Between Quality of Care for Breast Cancer and Health Insurance Exchange Coverage: An Analysis of Use of Radiation Therapy After Breast-Conserving Surgery.

Shih YT, Xu Y, Chavez-MacGregor M, Guadagnolo BA, Smith BD, Giordano SH.

JAMA Oncol. 2017 Oct 1;3(10):1425-1426. doi: 10.1001/jamaoncol.2017.1287. No abstract available.

31.

A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy.

Kuerer HM, Rauch GM, Krishnamurthy S, Adrada BE, Caudle AS, DeSnyder SM, Black DM, Santiago L, Hobbs BP, Lucci A Jr, Gilcrease M, Hwang RF, Candelaria RP, Chavez-MacGregor M, Smith BD, Arribas E, Moseley T, Teshome M, Miggins MV, Valero V, Hunt KK, Yang WT.

Ann Surg. 2018 May;267(5):946-951. doi: 10.1097/SLA.0000000000002313.

32.

Impact of the timing of hepatitis B virus identification and anti-hepatitis B virus therapy initiation on the risk of adverse liver outcomes for patients receiving cancer therapy.

Hwang JP, Suarez-Almazor ME, Cantor SB, Barbo A, Lin HY, Ahmed S, Chavez-MacGregor M, Donato-Santana C, Eng C, Ferrajoli A, Fisch MJ, McLaughlin P, Simon GR, Rondon G, Shpall EJ, Lok AS.

Cancer. 2017 Sep 1;123(17):3367-3376. doi: 10.1002/cncr.30729. Epub 2017 May 18.

33.

Personalized Prognostic Prediction Models for Breast Cancer Recurrence and Survival Incorporating Multidimensional Data.

Wu X, Ye Y, Barcenas CH, Chow WH, Meng QH, Chavez-MacGregor M, Hildebrandt MA, Zhao H, Gu X, Deng Y, Wagar E, Esteva FJ, Tripathy D, Hortobagyi GN.

J Natl Cancer Inst. 2017 Jul 1;109(7). doi: 10.1093/jnci/djw314.

34.

Outcomes in patients with early-stage breast cancer who underwent a 21-gene expression assay.

Barcenas CH, Raghavendra A, Sinha AK, Syed MP, Hsu L, Patangan MG Jr, Chavez-MacGregor M, Shen Y, Hortobagyi GH, Valero V, Giordano SH, Ueno NT, Tripathy D.

Cancer. 2017 Jul 1;123(13):2422-2431. doi: 10.1002/cncr.30618. Epub 2017 Feb 15.

35.

Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy.

Fujii T, Kogawa T, Wu J, Sahin AA, Liu DD, Chavez-MacGregor M, Giordano SH, Raghavendra A, Murthy RK, Tripathy D, Shen Y, Yamal JM, Ueno NT.

Br J Cancer. 2017 Feb 14;116(4):509-514. doi: 10.1038/bjc.2016.444. Epub 2017 Jan 12.

36.

Incremental Cancer Detection of Locoregional Restaging with Diagnostic Mammography Combined with Whole-Breast and Regional Nodal Ultrasound in Women with Newly Diagnosed Breast Cancer.

Candelaria RP, Huang ML, Adrada BE, Bassett R, Hunt KK, Kuerer HM, Smith BD, Chavez-MacGregor M, Yang WT.

Acad Radiol. 2017 Feb;24(2):191-199. doi: 10.1016/j.acra.2016.11.015. Epub 2016 Dec 7.

37.

Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab.

Basho RK, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Herbrich SM, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Ibrahim NK, Murray JL 3rd, Koenig KB, Hong D, Subbiah V, Kurzrock R, Janku F, Moulder SL.

JAMA Oncol. 2017 Apr 1;3(4):509-515. doi: 10.1001/jamaoncol.2016.5281.

PMID:
27893038
38.

Clinical outcomes based on multigene profiling in metastatic breast cancer patients.

Basho RK, de Melo Gagliato D, Ueno NT, Wathoo C, Chen H, Shariati M, Wei C, Alvarez RH, Moulder SL, Sahin AA, Roy-Chowdhuri S, Chavez-MacGregor M, Litton JK, Valero V, Luthra R, Zeng J, Shaw KR, Mendelsohn J, Mills GB, Tripathy D, Meric-Bernstam F.

Oncotarget. 2016 Nov 22;7(47):76362-76373. doi: 10.18632/oncotarget.12987.

39.

Guidelines for Guidelines: An Assessment of the American Society of Breast Surgeons Contralateral Prophylactic Mastectomy Consensus Statement.

Tuttle TM, Barrio AV, Klimberg VS, Giuliano AE, Chavez-MacGregor M, Buum HA, McMasters KM.

Ann Surg Oncol. 2017 Jan;24(1):1-2. doi: 10.1245/s10434-016-5648-7. Epub 2016 Oct 25. No abstract available.

40.

Initiation of and adherence to tamoxifen and aromatase inhibitor therapy among elderly women with ductal carcinoma in situ.

Zhao H, Hei N, Wu Y, Chan W, Lei X, Cameron C, Chang S, Chavez-MacGregor M, Giordano SH.

Cancer. 2017 May 15;123(6):940-947. doi: 10.1002/cncr.30425. Epub 2016 Oct 25.

41.

The Impact of Paravertebral Block Analgesia on Breast Cancer Survival After Surgery.

Cata JP, Chavez-MacGregor M, Valero V, Black W, Black DM, Goravanchi F, Ifeanyi IC, Hernandez M, Rodriguez-Restrepo A, Gottumukkala V.

Reg Anesth Pain Med. 2016 Nov/Dec;41(6):696-703.

PMID:
27685344
42.

Combining Clinical and Pathologic Staging Variables Has Prognostic Value in Predicting Local-regional Recurrence Following Neoadjuvant Chemotherapy for Breast Cancer.

Vila J, Teshome M, Tucker SL, Woodward WA, Chavez-MacGregor M, Hunt KK, Mittendorf EA.

Ann Surg. 2017 Mar;265(3):574-580. doi: 10.1097/SLA.0000000000001492.

PMID:
27735826
43.

Estimating regimen-specific costs of chemotherapy for breast cancer: Observational cohort study.

Giordano SH, Niu J, Chavez-MacGregor M, Zhao H, Zorzi D, Shih YT, Smith BD, Shen C.

Cancer. 2016 Nov 15;122(22):3447-3455. doi: 10.1002/cncr.30274. Epub 2016 Oct 10.

44.

Outcomes of Post Mastectomy Radiation Therapy in Patients Receiving Axillary Lymph Node Dissection After Positive Sentinel Lymph Node Biopsy.

Stauder MC, Caudle AS, Allen PK, Shaitelman SF, Smith BD, Hoffman KE, Buchholz TA, Chavez-Macgregor M, Hunt KK, Meric-Bernstam F, Woodward WA.

Int J Radiat Oncol Biol Phys. 2016 Nov 1;96(3):637-44. doi: 10.1016/j.ijrobp.2016.07.003. Epub 2016 Jul 13.

PMID:
27681760
45.

Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma in Situ.

Morrow M, Van Zee KJ, Solin LJ, Houssami N, Chavez-MacGregor M, Harris JR, Horton J, Hwang S, Johnson PL, Marinovich ML, Schnitt SJ, Wapnir I, Moran MS.

Pract Radiat Oncol. 2016 Sep-Oct;6(5):287-295. doi: 10.1016/j.prro.2016.06.011. Epub 2016 Jun 24.

46.

Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma In Situ.

Morrow M, Van Zee KJ, Solin LJ, Houssami N, Chavez-MacGregor M, Harris JR, Horton J, Hwang S, Johnson PL, Marinovich ML, Schnitt SJ, Wapnir I, Moran MS.

J Clin Oncol. 2016 Nov 20;34(33):4040-4046. doi: 10.1200/JCO.2016.68.3573. Epub 2016 Oct 31.

47.

Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery with Whole-Breast Irradiation in Ductal Carcinoma In Situ.

Morrow M, Van Zee KJ, Solin LJ, Houssami N, Chavez-MacGregor M, Harris JR, Horton J, Hwang S, Johnson PL, Marinovich ML, Schnitt SJ, Wapnir I, Moran MS.

Ann Surg Oncol. 2016 Nov;23(12):3801-3810. Epub 2016 Aug 15. Review.

48.

Clinicopathological and surgical factors associated with long-term survival in patients with HER2-positive metastatic breast cancer.

Harano K, Lei X, Gonzalez-Angulo AM, Murthy RK, Valero V, Mittendorf EA, Ueno NT, Hortobagyi GN, Chavez-MacGregor M.

Breast Cancer Res Treat. 2016 Sep;159(2):367-74. doi: 10.1007/s10549-016-3933-6. Epub 2016 Aug 13.

PMID:
27522517
49.

Nomograms for Predicting Axillary Response to Neoadjuvant Chemotherapy in Clinically Node-Positive Patients with Breast Cancer.

Vila J, Mittendorf EA, Farante G, Bassett RL, Veronesi P, Galimberti V, Peradze N, Stauder MC, Chavez-MacGregor M, Litton JF, Huo L, Kuerer HM, Hunt KK, Caudle AS.

Ann Surg Oncol. 2016 Oct;23(11):3501-3509. doi: 10.1245/s10434-016-5277-1. Epub 2016 May 23.

PMID:
27216742
50.

Short-term mortality in older patients treated with adjuvant chemotherapy for early-stage breast cancer.

Rosenstock AS, Lei X, Tripathy D, Hortobagyi GN, Giordano SH, Chavez-MacGregor M.

Breast Cancer Res Treat. 2016 Jun;157(2):339-350. doi: 10.1007/s10549-016-3815-y. Epub 2016 May 4.

PMID:
27146586

Supplemental Content

Loading ...
Support Center